Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore.

Tan, Ling Eng; Tan, Wan Hui Gloria; Aziz, Mohamed Ismail Abdul; Koh, Mariko Siyue; Tay, Tunn Ren; Pearce, Fiona; Ng, Kwong

Tan, Ling Eng; Tan, Wan Hui Gloria; Aziz, Mohamed Ismail Abdul; Koh, Mariko Siyue; Tay, Tunn Ren; Pearce, Fiona; Ng, Kwong.

Afiliação

Tan LE; Ministry of Health, Agency for Care Effectiveness, Singapore, Singapore.
Tan WHG; Ministry of Health, Agency for Care Effectiveness, Singapore, Singapore.
Aziz MIA; Ministry of Health, Agency for Care Effectiveness, Singapore, Singapore.
Koh MS; Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore, Singapore.
Tay TR; Office of Clinical, Academic and Faculty Affairs, Duke NUS Medical School, Singapore, Singapore.
Pearce F; Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore, Singapore.
Ng K; Ministry of Health, Agency for Care Effectiveness, Singapore, Singapore.

J Asthma ; 59(1): 189-199, 2022 Jan.

Article em En | MEDLINE | ID: mdl-33058740

Assuntos

Antiasmáticos; Asma; Eosinofilia Pulmonar; Antiasmáticos/uso terapêutico; Anticorpos Monoclonais Humanizados; Asma/tratamento farmacológico; Análise Custo-Benefício; Humanos; Eosinofilia Pulmonar/tratamento farmacológico; Anos de Vida Ajustados por Qualidade de Vida; Singapura; Padrão de Cuidado

Palavras-chave

Asthma; Markov; QALY; cost-effectiveness; cost-utility; mepolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Eosinofilia Pulmonar / Asma / Antiasmáticos Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: J Asthma Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Singapura

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google